Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 277

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults

Open access
Flood, David, Seiglie, Jacqueline A, Dunn, Matthew, Tschida, Scott, Theilmann, Michaela, Marcus, Maja E, Brian, Garry, Norov, Bolormaa, Mayige, Mary T, Gurung, Mongal Singh, Aryal, Krishna K, Labadarios, Demetre, Dorobantu, Maria, Silver, Bahendeka K, Bovet, Pascal, Jorgensen, Jutta M Adelin, Guwatudde, David, Houehanou, Corine, Andall-Brereton, Glennis, Quesnel-Crooks, Sarah, Sturua, Lela, Farzadfar, Farshad, Moghaddam, Sahar Saeedi, Atun, Rifat, Vollmer, Sebastian, Bärnighausen, Till W, Davies, Justine I, Wexler, Deborah J, Geldsetzer, Pascal, Rohloff, Peter, Ramírez-Zea, Manuel, Heisler, Michele, Manne-Goehler, Jennifer · 2021 · The Lancet Healthy Longevity

Abstract

Background Approximately 80% of the 463 million adults worldwide with diabetes live in low-income and middle-income countries (LMICs). A major obstacle to designing evidence-based policies to improve diabetes outcomes in LMICs is the scarce availability of nationally representative data on the current patterns of treatment coverage. The objectives of this study were to estimate the proportion of adults with diabetes in LMICs who receive coverage of recommended pharmacological and non-pharmacological diabetes treatment; and to describe country-level and individual-level characteristics that are associated with treatment. Methods We did a cross-sectional analysis of pooled, individual data from 55 nationally representative surveys in LMICs. Our primary outcome of self-reported diabetes treatment coverage was based on population-level monitoring indicators recommended in the 2020 WHO Package of Essential Noncommunicable Disease Interventions. Surveys were included if they were done in 2008 or after in an LMIC, as classified by the World Bank in the year the survey was done; were nationally representative; had individual-level data; contained a diabetes biomarker (fasting glucose, random glucose, or glycated haemoglobin); and had data on one or more diabetes treatments. Our sample included non-pregnant individuals with an available diabetes biomarker who were at least 25 years of age. We assessed coverage of three pharmacological and three non-pharmacological treatments among people with diabetes. At the country level, we estimated the proportion of individuals reporting coverage by per-capita gross national income and geographical region. At the individual level, we used logistic regression models to assess coverage along several key individual characteristics including sex, age, body-mass index, wealth quintile, and educational attainment. In the primary analysis, we scaled sample weights such that countries were weighted equally. Findings The final pooled sample from the 55 LMICs included 680 102 total individuals and 37 094 individuals with diabetes. Using equal weights for each country, diabetes prevalence was 9·0% (95% CI 8·7–9·4), with 43·9% (41·9–45·9) reporting a previous diabetes diagnosis. Overall, 4·6% (3·9–5·4) of individuals with diabetes self-reported meeting need for all treatments recommended for them. Coverage of glucose-lowering medication was 50·5% (48·6–52·5); antihypertensive medication was 41·3% (39·3–43·3); cholesterol-lowering medication was 6·3% (5·5–7·2); diet counselling was 32·2% (30·7–33·7); exercise counselling was 28·2% (26·6–29·8); and weight-loss counselling was 31·5% (29·3–33·7). Countries at higher-income levels tended to have greater coverage. Female sex and higher age, body-mass index, educational attainment, and household wealth were also associated with greater coverage. Interpretation Fewer than one in ten people with diabetes in LMICs receive coverage of guideline-based comprehensive diabetes treatment. Scaling up the capacity of health systems to deliver treatment not only to lower glucose but also to address cardiovascular disease risk factors, such as hypertension and high cholesterol, are urgent global diabetes priorities. Funding National Clinician Scholars Program at the University of Michigan Institute for Healthcare Policy & Innovation, National Institute of Diabetes and Digestive and Kidney Diseases, Harvard Catalyst, and National Center for Advancing Translational Sciences of the National Institutes of Health.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2666-7568(21)00089-1

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 277

Metadata

Authors
Flood, D., Seiglie, J. A., Dunn, M., Tschida, S., Theilmann, M., Marcus, M. E., Brian, G., Norov, B., Mayige, M. T., Gurung, M. S., Aryal, K. K., Labadarios, D., Dorobantu, M., Silver, B. K., Bovet, P., Jorgensen, J. M. A., Guwatudde, D., Houehanou, C., Andall-Brereton, G., Quesnel-Crooks, S., Sturua, L., Farzadfar, F., Moghaddam, S. S., Atun, R., Vollmer, S., Bärnighausen, T. W., Davies, J. I., Wexler, D. J., Geldsetzer, P., Rohloff, P., Ramírez-Zea, M., Heisler, M., & Manne-Goehler, J.
Venue
The Lancet Healthy Longevity
Publisher
Elsevier BV
Published
2021-06
Volume
2
Issue
6
Pages
e340-e351
ISSN
2666-7568 (ISSN-L)
OpenAlex
W3165161730
Cited by
277
References
42
FWCI
24.77
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults. https://app.cochat.ai/papers/10.1016/s2666-7568(21)00089-1
The paper
Flood, D., Seiglie, J. A., Dunn, M., Tschida, S., Theilmann, M., Marcus, M. E., Brian, G., Norov, B., Mayige, M. T., Gurung, M. S., Aryal, K. K., Labadarios, D., Dorobantu, M., Silver, B. K., Bovet, P., Jorgensen, J. M. A., Guwatudde, D., Houehanou, C., Andall-Brereton, G., . . . Manne-Goehler, J. (2021). The state of diabetes treatment coverage in 55 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 680 102 adults. The Lancet Healthy Longevity. https://doi.org/10.1016/s2666-7568(21)00089-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.